Abstract:Abstract A major hurdle in the treatment of inflammatory bowel disease (IBD) is the lack of effective drug carriers that can precisely deliver the required amount of drug to the sites of inflammation. Available therapies have limited efficacy or severe side effects, largely because of the low concentration of active drugs at the disease sites and non-specific systemic absorption of the administered drugs. Drug delivery targeting the sites of intestinal inflammation offers an approach to maximize therapeutic efficacy while minimizing adverse side effects. We focus on developing formulations that can provide improved local drug administration in the treatment of ulcerative colitis (UC), one of the two main types of IBD. Targeting sites of inflammation in the gastrointestinal tract can be achieved using drug delivery systems that exploit pathophysiological features of the inflamed intestine. Our previous study showed preferential adhesion of a negatively charged small-molecule-based hydrogel to the inflamed colon in murine models of colitis and biopsies from UC patients; further, a corticosteroid drug delivered by this hydrogel demonstrated an improved efficacy compared to the drug alone. Based on our previous experience, we expanded the small-molecule-based hydrogel to polymer-based hydrogels for enhanced selective targeting. We designed the material so that it has a strong affinity towards ulcers. Through molecular structure design, we functionalized thermo-responsive poly(N-isopropylacrylamide) (PNIPAM)-based polymers to modulate the physicochemical properties of the materials and compared the resultant polymers’ gelation and adhesion to the inflamed colon in dextran sulfate sodium (DSS)-induced colitis in mice. We showed that both the types of chemical modification and polymer molecular weight affected the adhesion of the resultant hydrogels to the inflamed colon. We further quantified the disease parameters of colitis for individual mice and correlated the colitis parameters with polymers’ adhesion. Our study suggests a new strategy for targeting the inflamed colon through harnessing charge-mediated interaction and thermo-responsiveness of PNIPAM-based polymers. By adhering to the inflamed mucosa, our delivery system has the potential to maintain the drug locally at the active ulcer sites where it is needed, thereby minimizing the adverse effects of drugs on the healthy tissue. The examination of these polymeric hydrogels’ mucosal binding provides a further understanding of interactions between the polymers and the biological interface in colitis. These studies were performed in preclinical models of UC that develop colitis similar to human UC, as a prerequisite for future studies.

Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Medicinal plant-based drug delivery system for inflammatory bowel disease

Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment

POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS

Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy

Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies

Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review

Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease

Advances in Carotenoid Based Delivery Systems for Alleviating Inflammatory Bowel Disease

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease

The Application of Natural Products-Delivering Micro/nano Systems in the Treatment of Inflammatory Bowel Disease

Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease

Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases

Novel drug delivery systems for inflammatory bowel disease.

Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

Advances in carbohydrate-based nanoparticles for targeted therapy of inflammatory bowel diseases: A review